Ironwood Pharmaceuticals Cash on Hand 2010-2024 | IRWD

Ironwood Pharmaceuticals cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Ironwood Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2023 $92
2022 $657
2021 $621
2020 $364
2019 $178
2018 $174
2017 $221
2016 $305
2015 $439
2014 $248
2013 $198
2012 $168
2011 $164
2010 $251
2009 $122
Ironwood Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $88
2024-06-30 $106
2024-03-31 $122
2023-12-31 $92
2023-09-30 $111
2023-06-30 $176
2023-03-31 $742
2022-12-31 $657
2022-09-30 $575
2022-06-30 $506
2022-03-31 $595
2021-12-31 $621
2021-09-30 $576
2021-06-30 $494
2021-03-31 $440
2020-12-31 $364
2020-09-30 $309
2020-06-30 $255
2020-03-31 $232
2019-12-31 $178
2019-09-30 $147
2019-06-30 $107
2019-03-31 $120
2018-12-31 $174
2018-09-30 $161
2018-06-30 $181
2018-03-31 $194
2017-12-31 $221
2017-09-30 $225
2017-06-30 $273
2017-03-31 $297
2016-12-31 $305
2016-09-30 $320
2016-06-30 $325
2016-03-31 $435
2015-12-31 $439
2015-09-30 $462
2015-06-30 $493
2015-03-31 $216
2014-12-31 $248
2014-09-30 $265
2014-06-30 $302
2014-03-31 $332
2013-12-31 $198
2013-09-30 $242
2013-06-30 $301
2013-03-31 $242
2012-12-31 $168
2012-09-30 $193
2012-06-30 $158
2012-03-31 $202
2011-12-31 $164
2011-09-30 $175
2011-06-30 $201
2011-03-31 $221
2010-12-31 $251
2010-09-30 $254
2010-06-30 $272
2010-03-31 $299
2009-12-31 $122
2009-09-30 $99
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.621B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $73.775B 28.39
Chugai Pharmaceutical (CHGCY) Japan $70.198B 27.35
Takeda Pharmaceutical (TAK) Japan $41.396B 8.62
Merck (MKKGY) Germany $18.461B 16.53
Sandoz Group AG (SDZNY) Switzerland $18.159B 0.00
Astellas Pharma (ALPMY) Japan $17.463B 16.08
United Therapeutics (UTHR) United States $16.079B 15.82
Neurocrine Biosciences (NBIX) United States $13.664B 36.18
Summit Therapeutics (SMMT) United States $13.569B 0.00
Shionogi (SGIOY) Japan $11.688B 11.71
Madrigal Pharmaceuticals (MDGL) United States $6.399B 0.00
Orion OYJ (ORINY) Finland $6.196B 17.42
Ionis Pharmaceuticals (IONS) United States $5.620B 0.00
Corcept Therapeutics (CORT) United States $5.359B 40.60
Crinetics Pharmaceuticals (CRNX) United States $4.891B 0.00
PTC Therapeutics (PTCT) United States $3.490B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.560B 11.60
Dyne Therapeutics (DYN) United States $2.473B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.401B 14.35
NewAmsterdam Pharma (NAMS) Netherlands $2.352B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.314B 0.00
Soleno Therapeutics (SLNO) United States $1.949B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.746B 0.00
Xencor (XNCR) United States $1.680B 0.00
Indivior (INDV) United States $1.591B 6.48
Evotec AG (EVO) Germany $1.559B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.531B 0.00
Guardian Pharmacy Services (GRDN) United States $1.382B 0.00
Ocular Therapeutix (OCUL) United States $1.328B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.294B 0.00
Harrow (HROW) United States $1.226B 0.00
Enliven Therapeutics (ELVN) United States $1.117B 0.00
Ardelyx (ARDX) United States $1.111B 0.00
ARS Pharmaceuticals (SPRY) United States $1.100B 0.00
Collegium Pharmaceutical (COLL) United States $0.982B 5.36
Avadel Pharmaceuticals (AVDL) Ireland $0.974B 0.00
Bioventus (BVS) United States $0.854B 26.97
Oruka Therapeutics (ORKA) United States $0.727B 0.00
Cronos Group (CRON) Canada $0.715B 0.00
Relay Therapeutics (RLAY) United States $0.713B 0.00
USANA Health Sciences (USNA) United States $0.662B 12.27
Elite Pharmaceuticals (ELTP) United States $0.609B 0.00
Altimmune (ALT) United States $0.582B 0.00
Savara (SVRA) United States $0.554B 0.00
Tourmaline Bio (TRML) United States $0.522B 0.00
Xeris Biopharma Holdings (XERS) United States $0.508B 0.00
OmniAb (OABI) United States $0.494B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.478B 0.00
Zevra Therapeutics (ZVRA) United States $0.456B 0.00
Verve Therapeutics (VERV) United States $0.437B 0.00
Siga Technologies (SIGA) United States $0.431B 5.03
Esperion Therapeutics (ESPR) United States $0.429B 0.00
ProKidney (PROK) United States $0.426B 0.00
Organogenesis (ORGO) United States $0.412B 0.00
Korro Bio (KRRO) United States $0.404B 0.00
KalVista Pharmaceuticals (KALV) United States $0.400B 0.00
Akebia Therapeutics (AKBA) United States $0.391B 0.00
Aquestive Therapeutics (AQST) United States $0.332B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.303B 122.93
Avita Medical (RCEL) United States $0.301B 0.00
Aldeyra Therapeutics (ALDX) United States $0.289B 0.00
Nature's Sunshine Products (NATR) United States $0.280B 16.63
Amylyx Pharmaceuticals (AMLX) United States $0.271B 0.00
4D Molecular Therapeutics (FDMT) United States $0.267B 0.00
Larimar Therapeutics (LRMR) United States $0.254B 0.00
Heron Therapeutics (HRTX) United States $0.233B 0.00
Innate Pharma SA (IPHYF) France $0.233B 0.00
Profound Medical (PROF) Canada $0.219B 0.00
Inhibikase Therapeutics (IKT) United States $0.212B 0.00
Acrivon Therapeutics (ACRV) United States $0.208B 0.00
Lexeo Therapeutics (LXEO) United States $0.200B 0.00
Aclaris Therapeutics (ACRS) United States $0.198B 0.00
Silence Therapeutics (SLN) United Kingdom $0.190B 0.00
Lyell Immunopharma (LYEL) United States $0.187B 0.00
MediWound (MDWD) Israel $0.186B 0.00
Nektar Therapeutics (NKTR) United States $0.174B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.162B 0.00
Nanobiotix S.A (NBTX) France $0.155B 0.00
CytoDyn (CYDY) United States $0.150B 0.00
Metagenomi (MGX) United States $0.144B 0.00
VAXART, INC (VXRT) United States $0.137B 0.00
Telomir Pharmaceuticals (TELO) United States $0.134B 0.00
Achieve Life Sciences (ACHV) Canada $0.131B 0.00
Galectin Therapeutics (GALT) United States $0.126B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Cassava Sciences (SAVA) United States $0.110B 0.00
Cardiol Therapeutics (CRDL) Canada $0.107B 0.00
Protara Therapeutics (TARA) United States $0.107B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.107B 0.00
Champions Oncology (CSBR) United States $0.104B 0.00
Regulus Therapeutics (RGLS) United States $0.102B 0.00
Inotiv (NOTV) United States $0.100B 0.00
Journey Medical (DERM) United States $0.097B 0.00
ElectroCore (ECOR) United States $0.095B 0.00
Avalo Therapeutics (AVTX) United States $0.094B 0.00
Pyxis Oncology (PYXS) United States $0.092B 0.00
Century Therapeutics (IPSC) United States $0.089B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
Karyopharm Therapeutics (KPTI) United States $0.082B 0.00
Context Therapeutics (CNTX) United States $0.082B 0.00
Assertio Holdings (ASRT) United States $0.080B 21.08
Arch Biopartners (ACHFF) Canada $0.078B 0.00
PMV Pharmaceuticals (PMVP) United States $0.078B 0.00
Unicycive Therapeutics (UNCY) United States $0.074B 0.00
ESSA Pharma (EPIX) Canada $0.071B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Scienture Holdings (SCNX) United States $0.070B 0.00
OptiNose (OPTN) United States $0.064B 0.00
Mural Oncology (MURA) Ireland $0.053B 0.00
AlloVir (ALVR) United States $0.052B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.050B 0.00
Prelude Therapeutics (PRLD) United States $0.049B 0.00
Iterum Therapeutics (ITRM) Ireland $0.048B 0.00
Nutriband (NTRB) United States $0.047B 0.00
Rafael Holdings (RFL) United States $0.044B 0.00
Gain Therapeutics (GANX) United States $0.042B 0.00
CASI Pharmaceuticals (CASI) China $0.042B 0.00
SCYNEXIS (SCYX) United States $0.038B 0.00
BioVie (BIVI) United States $0.037B 0.00
FibroGen (FGEN) United States $0.036B 0.00
VYNE Therapeutics (VYNE) United States $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.033B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.033B 0.00
Surrozen (SRZN) United States $0.032B 0.00
Incannex Healthcare (IXHL) Australia $0.031B 0.00
Tempest Therapeutics (TPST) United States $0.031B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.031B 0.00
DURECT (DRRX) United States $0.027B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
Lipocine (LPCN) United States $0.025B 0.00
Vivos Therapeutics (VVOS) United States $0.023B 0.00
Mannatech (MTEX) United States $0.022B 0.00
Citius Pharmaceuticals (CTXR) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
NRx Pharmaceuticals (NRXP) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
MEI Pharma (MEIP) United States $0.016B 0.00
BioLineRx (BLRX) Israel $0.016B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
Cosmos Health (COSM) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.013B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.013B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Nuvilex (PMCB) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.011B 0.00
Relmada Therapeutics (RLMD) United States $0.011B 0.00
Talphera (TLPH) United States $0.011B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
Klotho Neurosciences (KLTO) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Indaptus Therapeutics (INDP) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.009B 0.00
Viracta Therapeutics (VIRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Dominari Holdings (DOMH) United States $0.008B 0.00
Redhill Biopharma (RDHL) Israel $0.008B 0.00
CERo Therapeutics Holdings (CERO) United States $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
Conduit Pharmaceuticals (CDT) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Bio-Path Holdings (BPTH) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.006B 0.00
Biomerica (BMRA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.10
SHINECO (SISI) China $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
TransCode Therapeutics (RNAZ) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Molecular Templates (MTEM) United States $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Phio Pharmaceuticals (PHIO) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
Jupiter Neurosciences (JUNS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 4.69
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 41.84